GANX241220C4000
- 0.00
- 0.000.00%
Gain Therapeutics Newsroom
Promising Preclinical Data and Financial Position Support Buy Rating for Gain Therapeutics
Chardan Capital Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $6
Gain Therapeutics Advances Parkinson's Therapy Development
Gain Therapeutics Receives Buy Rating as GT-02287 Shows Promise for GBA1 Parkinson's Disease
Gain Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q3 EPS Results.
Gain Therapeutics | 8-K: Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
Gain Therapeutics Q3 2024 GAAP EPS $(0.17) Beats $(0.21) Estimate
Gain Therapeutics | 10-Q: Q3 2024 Earnings Report
Express News | Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
Gain Therapeutics Shares Are Trading Higher After the Company Announced He Presentation of a Poster That Details the Use of Its Magellan Drug Discovery Platform to Identify Allosteric Inhibitors Targeting Discoidin Domain Receptor 2.
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Gain Therapeutics to Present at Michael J. Fox Foundation's 16th Annual Parkinson's Disease Therapeutics Conference
Gain Therapeutics Excels in Neurodegenerative Drug Trials
Gain Therapeutics Announced The Presentation Of New Evidence Supporting The Disease-modifying Activity Of Gt-02287 In Preclinical Animal Models Of Both GBA-1 And Idiopathic Parkinson's Disease
Gain Therapeutics to Participate at Upcoming Investor Conferences
Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $5
H.C. Wainwright Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8
BTIG Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $10
Gain Therapeutics Shares Are Trading Lower. The Company Announced the Presentation of a Late-breaking Abstract at the International Congress of Parkinson's Disease and Movement Disorders.